Eisai and Merck (MSD outside of the US and Canada) have announced that in a Phase III trial, Lenvima (lenvatinib) plus Keytruda (pembrolizumab) with transarterial chemoembolisation (TACE) did not achieve statistical significance for overall survival (OS) compared to TACE alone.  

The LEAP-012 trial evaluated the combination in patients with unresectable, non-metastatic hepatocellular carcinoma (HCC). 

At a pre-specified interim analysis, the likelihood of reaching the protocol-specified threshold for statistical significance for OS at a future analysis was considered to be low. On this basis, the study will be closed, and the companies are informing investigators of this decision. Further analysis of the data is ongoing 

The combination therapy met the study’s other primary endpoint of progression-free survival (PFS) and demonstrated a statistically significant and clinically meaningful improvement compared to TACE alone. 

“Although the progression-free survival results from this study are encouraging, unfortunately, the addition of Keytruda plus Lenvima to TACE did not show the overall survival benefit we hoped,” said Dr Gregory Lubiniecki, Vice President, Global Clinical Development, MSD Research Laboratories. 

In July 2025, Lenvima plus Keytruda in combination with TACE was approved in China to treat unresectable non-metastatic HCC. The Lenvima plus Keytruda combination is approved in the US, the European Union (EU), Japan and other countries for the treatment of advanced renal cell carcinoma (RCC) and certain types of advanced endometrial carcinoma. 

Dr Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai, said: “For years, TACE has been a standard of care for these patients, yet many experience disease progression within twelve months. With LEAP-012, we sought to make a meaningful difference for this patient population. Lenvima continues to play an important role as a monotherapy treatment option for patients with unresectable HCC.” 

Diana Turner, Deputy Editor, DDW